Zacks Small Cap Research on MSN16h
IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001…
IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with ...
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment ...
Horse and Hound1d
Willberry Wonder Pony funds new research into rare cancer in young rider’s memory
A protein named interleukin-12 (IL-12) is known to successfully activate anti-tumour immune cells against several cancers.
clinicaladvisor.com11d
New Presentation, Indications Approved for Biosimilar Selarsdi
The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...
Medical Xpress20d
Bioengineers shed light on dosing challenges for cancer immunotherapy
A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12)—a potent immune-boosting protein that holds promise for cancer treatment ...